Company / Financials
aTYR PHARMA INC Financials
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$190.0K
FY2025 · -19.1% YoY
Net Income
-$74.1M
FY2025 · -15.8% YoY
Profit Margin
-39009.5%
FY2025 · net income / revenue
ROE
-109.8%
FY2025 · return on equity
Total Assets
$93.0M
FY2025
Total Debt
-
FY2025
Equity
$67.5M
FY2025
ROA
-79.7%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$190.0K-19.1% YoYNet Income HistoryProfit after all expenses and taxes-$74.1M-15.8% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$77.6M-14.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$17.6M+27.7% YoYR&D Expense HistoryResearch and development spending$60.2M+10.8% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$0.94+41.3% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.94+41.3% YoYShares Outstanding HistoryWeighted average diluted shares outstanding84.0M+32.8% YoYTotal Assets HistoryTotal value of all assets owned$93.0M-4.0% YoY